Deborah Doss

4.4k total citations · 1 hit paper
34 papers, 2.0k citations indexed

About

Deborah Doss is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Deborah Doss has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 16 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Deborah Doss's work include Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (10 papers) and Cancer Treatment and Pharmacology (9 papers). Deborah Doss is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (10 papers) and Cancer Treatment and Pharmacology (9 papers). Deborah Doss collaborates with scholars based in United States, India and Germany. Deborah Doss's co-authors include Kenneth C. Anderson, Robert Schlossman, Hani Doss, Randall E. Harris, Constantine S. Mitsiades, Edie Weller, Paul G. Richardson, Andrea Freeman, Teru Hideshima and Mary McKenney and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Mayo Clinic Proceedings.

In The Last Decade

Deborah Doss

33 papers receiving 1.9k citations

Hit Papers

Immunomodulatory drug CC-5013 overcomes drug resistance a... 2002 2026 2010 2018 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    2002 630 citations Paul G. Richardson, Robert Schlossman et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Doss United States 14 1.3k 1.1k 860 244 230 34 2.0k
Diana Cirstea United States 22 894 0.7× 1.6k 1.5× 1.1k 1.3× 168 0.7× 188 0.8× 80 2.4k
Ji Yuan Wu United States 21 908 0.7× 712 0.7× 666 0.8× 803 3.3× 168 0.7× 44 2.1k
Lance Leopold United States 24 473 0.4× 1.1k 1.0× 1.4k 1.6× 215 0.9× 594 2.6× 50 2.8k
Kaori Shinjo Japan 21 577 0.5× 568 0.5× 323 0.4× 167 0.7× 111 0.5× 51 1.1k
Hui Lin China 18 935 0.7× 741 0.7× 304 0.4× 733 3.0× 110 0.5× 50 1.8k
Mingjie Li United States 19 682 0.5× 583 0.5× 624 0.7× 109 0.4× 276 1.2× 94 1.4k
Giovanni Roti Italy 23 575 0.5× 823 0.8× 312 0.4× 212 0.9× 115 0.5× 57 1.5k
Elie Traer United States 21 666 0.5× 1.1k 1.0× 353 0.4× 268 1.1× 245 1.1× 64 1.8k
Florian H. Heidel Germany 30 1.8k 1.4× 1.7k 1.5× 509 0.6× 995 4.1× 312 1.4× 143 3.1k
Rachel Neuwirth United States 18 615 0.5× 689 0.6× 454 0.5× 125 0.5× 90 0.4× 47 1.2k

Countries citing papers authored by Deborah Doss

Since Specialization
Citations

This map shows the geographic impact of Deborah Doss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Doss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Doss more than expected).

Fields of papers citing papers by Deborah Doss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Doss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Doss. The network helps show where Deborah Doss may publish in the future.

Co-authorship network of co-authors of Deborah Doss

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Doss. A scholar is included among the top collaborators of Deborah Doss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Doss. Deborah Doss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Doss, Deborah, et al.. (2024). Ai-Powered Personalized Learning System Design: Student Engagement And Performance Tracking System. 1125–1130. 8 indexed citations
2.
3.
Doss, Deborah, et al.. (2020). RESPIRATORY MUSCLE TRAINING WITH THERABAND VERSUS INCENTIVE SPIROMETER AMONG INDIVIDUALS WITH BRONCHIAL ASTHMA. International Journal of Current Pharmaceutical Research. 117–120. 1 indexed citations
4.
Doss, Deborah, et al.. (2019). Biofeedback Flutter Device. Biomedical & Pharmacology Journal. 12(2). 793–798. 1 indexed citations
5.
Richardson, Paul G., Craig C. Hofmeister, Noopur Raje, et al.. (2017). Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 31(12). 2695–2701. 26 indexed citations
6.
Faiman, Beth, et al.. (2017). Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma. Clinical journal of oncology nursing. 21(5). 19–36. 7 indexed citations
7.
Richardson, Paul G., Jacob P. Laubach, Robert Schlossman, et al.. (2012). The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. European Journal Of Haematology. 88(5). 446–449. 8 indexed citations
8.
Richards, Tiffany, et al.. (2011). Sexual Dysfunction in Multiple Myeloma. Clinical journal of oncology nursing. 15(0). 53–65. 10 indexed citations
9.
Richardson, Paul G., Wanling Xie, Constantine S. Mitsiades, et al.. (2009). Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. Journal of Clinical Oncology. 27(21). 3518–3525. 200 indexed citations
10.
11.
Bilotti, Elizabeth, Kathleen Colson, Kathleen M. Curran, et al.. (2008). Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation's Nurse Leadership Board. Clinical journal of oncology nursing. 12(0). 9–12. 13 indexed citations
12.
Colson, Kathleen, Deborah Doss, Regina A. Swift, & Joseph D Tariman. (2008). Expanding Role of Bortezomib in Multiple Myeloma. Cancer Nursing. 31(3). 239–249. 7 indexed citations
13.
Doss, Deborah, et al.. (2008). Thromboembolic Events Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board. Clinical journal of oncology nursing. 12(0). 21–28. 14 indexed citations
14.
Doss, Deborah. (2006). Advances in Oral Therapy in the Treatment of Multiple Myeloma. Clinical journal of oncology nursing. 10(4). 514–520. 7 indexed citations
15.
Mitsiades, Constantine S., Asher Chanan‐Khan, Melissa Alsina, et al.. (2005). Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM). Journal of Clinical Oncology. 23(16_suppl). 3056–3056. 4 indexed citations
16.
Richardson, Paul G., Asher Chanan‐Khan, Melissa Alsina, et al.. (2005). Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial.. Blood. 106(11). 361–361. 27 indexed citations
17.
18.
19.
Richardson, Paul G., Robert Schlossman, Edie Weller, et al.. (2002). Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 100(9). 3063–3067. 630 indexed citations breakdown →
20.
Richardson, PG, RL Schlossman, Teru Hideshima, et al.. (2001). A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).. Blood. 98(11). 77516. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diana Cirstea Breakdown of academic impact, for papers by Ji Yuan Wu Breakdown of academic impact, for papers by Lance Leopold Breakdown of academic impact, for papers by Kaori Shinjo Breakdown of academic impact, for papers by Hui Lin Breakdown of academic impact, for papers by Mingjie Li Breakdown of academic impact, for papers by Giovanni Roti Breakdown of academic impact, for papers by Elie Traer Breakdown of academic impact, for papers by Florian H. Heidel Breakdown of academic impact, for papers by Rachel Neuwirth
Rankless by CCL
2026